Oral lesions presenting as an early sign of acute leukaemia.

To cite: Vourexakis Z. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2014205100 DESCRIPTION A middle-aged patient with no major comorbidity presented to the emergency department with severe odynophagia and painful oral lesions of 3 days’ duration, and pronounced fatigue along with unusual recurrent bruising for almost a month. Inspection of the oral cavity (figures 1 and 2) revealed ecchymoses on the hard palate and the floor of the mouth (blue arrows), ulcerations (white arrows) and pallor of the oral mucosa. The work-up included a complete blood count, karyotyping, microscopic examination and molecular biology studies of bone marrow biopsies. Severe pancytopenia (5 platelets/nL, 1.1 leucocytes/nL and 22% haematocrit) along with a t(15;17)(q24;q21) translocation were identified and findings were all compatible with the diagnosis of acute promyelocytic leukaemia (APML). Despite appropriate treatment, the patient died from intracranial haemorrhage occurring 3 weeks after initial admission to the hospital. At initial presentation of leukaemia, oral manifestations may be present in 2/3 of all patients. None of these lesions is specific for the disease. It is the simultaneous presence of different types of oral lesions (haematomas, ulcers, gingival hypertrophy, opportunistic infections, etc) that should alert the physician. As APML represents one of the most curable but also most aggressive subtypes of acute leukaemia when left untreated, rapid and accurate diagnosis are crucial in its management. The treatment’s efficacy increases drastically with the association of anthracycline-based chemotherapy regimens to a vitamin A derivative, the all-trans retinoic acid, with or without arsenic trioxide. Nowadays, the 5-year disease-free survival of properly treated patients with APML may be well above 75%. Nevertheless, lifethreatening coagulopathy and lethal bleeding still represent a major risk for these patients.